Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taiho Pharmaceutical is set to introduce Abraxane IV Infusion 100mg, an antineoplastic for injectable suspension (paclitaxel albumin-bound particles for injectable suspension) on 24 September 2010.
Subscribe to our email newsletter
Taiho Pharma said that Abraxane features improved efficacy and safety as well as easier administration compared to solvent-based paclitaxel.
Originally, Abraxane was developed by Abraxis BioScience as a novel paclitaxel formulation for breast cancer treatment.
The US Food and Drug Administration has granted approval for the drug in January 2005.